Samsung Bioepis said that it has obtained a sales approval for Aybintio, a biosimilar for metastatic colon cancer and non-small cell lung cancer, from the European Commission (EC).
|Samsung Bioepis has won sales approval for an Avastin biosimilar in the EU. (Samsung Bioepis)|
Aybintio is a biosimilar of Avastin developed by Roche, which kills cancer cells by removing blood vessels. Avastin scored sales of 8.5 trillion won ($7.1 billion) globally last year, and the EU market alone is sized at 2.2 trillion won.
The approval comes after the company won a positive opinion for Aybintio from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in June. Also, Samsung Bioepis has become the first Korean company that won the approval for an Avastin biosimilar in the EU.
“By securing the fifth biosimilar in the global market, the company has laid the foundation to leap forward as an industry leader,” Samsung Bioepis CEO Ko Han-sung said. “Through Aybintio, we will expand opportunities for cancer patients to be treated with high-quality biopharmaceuticals.”
<© Korea Biomedical Review, All rights reserved.>